Dmitry Balyasny’s BioCryst Pharmaceuticals BCRX Stock Holding History

Dmitry Balyasny’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-900,000	Closed	-$1.8M	–	1129
2020 Q1	$1.8M	Buy	+900,000	New	+$2.48M	0.02%	634

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Dmitry Balyasny's BCRX Position: Q2 2026 in Review

Dmitry Balyasny sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 186,125 shares — an estimated $1.77M sold.

Dmitry Balyasny first reported a position in BCRX in Q2 2015 and held it in 13 quarters. The position peaked at $15.4M in Q3 2022. 316 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Dmitry Balyasny reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Dmitry Balyasny sold 186,125 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.77M.
Dmitry Balyasny first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 13 quarters.
Dmitry Balyasny's BioCryst Pharmaceuticals position peaked at $15.4M in Q3 2022.
316 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.